Securities code: 600488 Securities abbreviation: Jinyao Pharmaceutical No.: 2026-007
Jinyao Pharmaceutical Co., Ltd.
Regarding the products of the company and its subsidiaries that are planned to be selected for centralized drug procurement organized by the country
Announcement on the continuation of procurement of varieties upon expiration of the agreement
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Recently, Jinyao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") and its holding subsidiaries participated in the continuation procurement of the 1-8 batches of national centralized procurement drugs upon expiration of the agreement (hereinafter referred to as "this continuation procurement") organized by the State-Organized Procurement Office for the Expiration of Agreements on Centralized Drugs (hereinafter referred to as the "Continuation Procurement Office"). According to the "Announcement of Result of Proposed Continuation Procurement of Variety Expiration of the National Organized Centralized Drug Purchase Agreement" issued by the Continuation Procurement Office on February 10, 2026, some drugs of the company and its holding subsidiaries are planned to be selected for this continuation procurement. The relevant information is now announced as follows:
1. Basic information on the drugs to be selected
Note: This continuation procurement information is subject to the final data released by the Continuation Procurement Office.
2. The impact of this proposed election on the company
According to this continued procurement rule, the company is temporarily unable to obtain the accurate supply price and quantity. The procurement cycle for the drugs to be selected this time is from the date of execution of the winning results to December 31, 2028.
The total sales revenue of the drugs to be selected by the company in 2024 will be RMB 323 million, accounting for 10.03% of the company's operating income in the same period; the sales revenue in the first three quarters of 2025 will total RMB 250 million (unaudited), accounting for 11.20% of the company's operating income in the same period.
The winning results of this continued procurement are expected to be implemented by the end of March 2026, that is, medical institutions in each province will begin to sign purchasing contracts with manufacturers based on the winning results and purchase on a rolling basis. If the subsequent purchase contract is signed and implemented, it will further expand product sales, increase market share, enhance the company's brand image, and promote the further development of the company's preparation business.
3. Risk warning
At present, the subsequent matters such as the signing of the purchase agreement for the above-mentioned drugs and the implementation of market sales are still uncertain. Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Jinyao Pharmaceutical Co., Ltd.
February 12, 2026
